Nektar Q2 FY26 net loss narrows to $40.62 million; revenue falls 9.35% to $10.1 million

Reuters2026/08/13 20:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nektar Therapeutics posted a Q2 net loss of $40.62 million, narrowing from $41.59 million a year earlier.
Loss per share narrowed to $1.23 from $2.95, while revenue slipped to $10.13 million from $11.18 million.
Operating costs and expenses rose to $52.47 million from $47.41 million, driven by higher R&D of $39.13 million versus $29.89 million.
Cash and marketable securities climbed to $1.02 billion at June 30 from $245.8 million at Dec. 31, following a $373.8 million stock offering.
Phase 3 ZENITH AD trials in atopic dermatitis began in July; a registrational Phase 3 alopecia areata study is planned for early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608131615PR_NEWS_USPR_____SF24211) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nektar Q2 FY26 net loss narrows to $40.62 million; revenue falls 9.35% to $10.1 million

You may also like

Crypto prices